美国食品和药品管理局(FDA)于2010年12月17日发布公告:停止注射用甲磺酸多拉司琼(dolasetron mesylate)用于预防化疗引起的恶心呕吐[1]。甲磺酸多拉司琼是强效、高选择性5-HT3受体拮抗剂,通过阻断中枢和外周神经系统的5-HT3受体而发挥镇吐作用。甲 The U.S. Food and Drug Administration (FDA) announced on December 17, 2010 that dolasetron mesylate for injection was discontinued for the prevention of chemotherapy-induced nausea and vomiting [1]. Dolastomesylate is a potent and highly selective 5-HT3 receptor antagonist that exerts antiemetic effects by blocking 5-HT3 receptors in the central and peripheral nervous systems. A